Presented at ESTRO 2025 in Vienna, Austria, a 10-year study involving over 4,000 UK patients confirms that a one-week course of post-surgery radiotherapy is just as safe and effective as the traditional three-week regimen for early-stage breast cancer patients. These long-term results from the FAST-Forward trial could further reduce the burden on breast cancer patients worldwide, and expand access to life-saving radiotherapy.
This article was originally published on MedicalXpress.com